In a person with type 1 diabetes taking a GLP‑1 receptor agonist (e.g., liraglutide, semaglutide) for weight loss, how should diabetic retinopathy be screened and managed?

Retinopathy Screening and Management in Type 1 Diabetes Patients on GLP-1 Receptor Agonists for Weight Loss

Before initiating any GLP-1 receptor agonist in a person with type 1 diabetes, obtain a dilated comprehensive eye examination to document baseline retinopathy status, and if any retinopathy is present—especially moderate or worse—increase monitoring frequency to every 3-6 months during the first year of treatment due to the risk of early worsening from rapid A1C reduction. 1, 2

Pre-Treatment Assessment

Mandatory baseline evaluation:

• Dilated comprehensive eye examination by an ophthalmologist or optometrist to grade retinopathy severity
• Document current A1C and calculate anticipated A1C reduction
• Assess duration of diabetes (type 1 patients with >10 years duration are higher risk)
• Review history of prior retinopathy treatment or complications

The 2025 ADA Standards explicitly state that retinopathy status should be assessed when glucose-lowering therapies are intensified, particularly with GLP-1 RAs, since rapid A1C reductions can cause initial worsening of retinopathy 1. The FDA label for semaglutide confirms this risk, noting that rapid improvement in glucose control has been associated with temporary worsening of diabetic retinopathy 2.

Risk Stratification and Monitoring Algorithm

For patients WITHOUT baseline retinopathy:

• Proceed with GLP-1 RA initiation
• Follow standard type 1 diabetes screening: annual dilated eye exams 3, 1
• Risk of new-onset retinopathy appears minimal (0.7% in semaglutide trials vs 0.4% placebo) 2

For patients WITH any baseline retinopathy:

• High-risk scenario (moderate-to-severe NPDR or worse, or anticipated A1C drop >1.0%):

  • Strongly consider ophthalmology consultation before initiating GLP-1 RA
  • If proceeding, schedule follow-up eye exams every 3-6 months during first year
  • Titrate GLP-1 RA more gradually to minimize rapid A1C reduction
  • The absolute risk increase is substantial: 8.2% vs 5.2% for retinopathy complications in those with baseline retinopathy 2

• Lower-risk scenario (mild NPDR, well-controlled diabetes):

  • May proceed with standard initiation
  • Increase monitoring to every 6 months for first year
  • Return to annual exams if stable

The Evidence Behind Early Worsening

The concern about GLP-1 RAs and retinopathy stems primarily from the SUSTAIN-6 trial with semaglutide, which showed increased retinopathy complications (3.0% vs 1.8% placebo) 2. However, multiple lines of evidence indicate this reflects the phenomenon of early worsening from rapid glycemic improvement rather than direct drug toxicity:

• Meta-analyses show the association between GLP-1 RAs and retinopathy correlates with the magnitude of A1C reduction, not the drug itself 1, 4
• This early worsening phenomenon is well-established from intensive insulin therapy trials (DCCT showed similar transient worsening)
• The effect appears time-limited to the period of rapid A1C change 4, 5
• No intrinsic retinotoxic mechanism has been identified 6, 7, 5

Long-Term Perspective

The cardiovascular and metabolic benefits of GLP-1 RAs substantially outweigh the transient retinopathy risk in most patients. 8, 4 The number needed to treat for cardiovascular benefit is 43-77, while the number needed to harm for retinopathy worsening is 77-1000 depending on baseline risk 4. Expert consensus affirms that GLP-1 RA benefits outweigh potential ocular risks and should not limit access to these medications 8.

Common Pitfalls to Avoid

1. Don't skip baseline eye examination - This is the single most critical error. You cannot assess risk or monitor appropriately without knowing baseline retinopathy status.

2. Don't assume "no symptoms = no retinopathy" - Patients may have good vision with significant retinopathy requiring treatment 3. Educate patients explicitly about this disconnect.

3. Don't discontinue GLP-1 RA at first sign of retinopathy progression - Early worsening may be transient. Coordinate closely with ophthalmology to determine if intervention (laser, anti-VEGF) can manage the retinopathy while continuing the GLP-1 RA for its systemic benefits.

4. Don't forget to optimize other risk factors - Maintain blood pressure and lipid control, which independently affect retinopathy progression 3, 1.

Special Considerations for Type 1 Diabetes

While GLP-1 RAs are not FDA-approved for type 1 diabetes, they are increasingly used off-label for weight loss and glycemic improvement 9. The retinopathy considerations are identical to type 2 diabetes, but remember:

• Type 1 patients develop retinopathy faster than type 2 (20.1% vs 7.2% over 3 years) 3
• Baseline screening should have occurred 5 years after diabetes onset per guidelines 3, 1
• If not previously screened, obtain baseline exam immediately before GLP-1 RA initiation

Documentation and Communication

Document in the medical record:

• Baseline retinopathy status and date of examination
• Discussion of retinopathy risk with patient
• Monitoring plan based on risk stratification
• Communication with ophthalmology regarding GLP-1 RA initiation

Ensure bidirectional communication between primary care/endocrinology and ophthalmology, particularly when initiating therapy in patients with known retinopathy 8, 4.